Who We Are
Patients are at the beginning, middle, and heart of all we do.
Harmony Biosciences is an innovative biopharmaceutical company dedicated to identifying, developing, and commercializing novel treatment options for patients with rare diseases. With an emphasis on central nervous system disorders, our goal is to push the boundaries of what science can do to improve the lives of patients.
What We Believe
Our primary mission is to have a positive impact on the lives of those who are so often underserved. We believe it takes both scientific vision and tenacity to pursue new therapies that will have the potential to transform the lives of patients.
Where We’re Starting
Our initial work is focused on the development, registration, and marketing of the drug pitolisant, a selective histamine H3-receptor antagonist/inverse agonist for the potential treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. To date, no H3-receptor antagonist/inverse agonist has been approved by the US Food & Drug Administration.
We believe there is tremendous potential for pitolisant to help patients in need, and we are both proud and excited to be a part of potentially bringing this new therapy to the United States.
Our company is led by a passionate team of industry veterans with a proven track record of success in developing and commercializing novel treatments for patients.
MAY 31, 2018
Harmony Biosciences To Present Data On Its Investigational Product, Pitolisant, At Upcoming SLEEP Annual Meeting
MAY 21, 2018
Harmony Biosciences Receives Breakthrough Therapy And Fast Track Designations For Pitolisant
Expanded Access Program For Pitolisant Is Open
October 5, 2017
Harmony Biosciences Acquires US Rights To Pitolisant From Bioprojet; Raises $270 Million In Equity Financing